FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2379-2388 June 9, 2005 Number 23 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease.

Methods In a double-blind study, we evaluated subjects with the amnestic subtype of mild cognitive impairment. Subjects were randomly assigned to receive 2000 IU of vitamin E daily, 10 mg of donepezil daily, or placebo for three years. The primary outcome was clinically possible or probable Alzheimer's disease; secondary outcomes were cognition and function.

Results A total of 769 subjects were enrolled, and possible or probable Alzheimer's disease developed in 212. The overall rate of progression from mild cognitive impairment to Alzheimer's disease was 16 percent per year. As compared with the placebo group, there were no significant differences in the probability of progression to Alzheimer's disease in the vitamin E group (hazard ratio, 1.02; 95 percent confidence interval, 0.74 to 1.41; P=0.91) or the donepezil group (hazard ratio, 0.80; 95 percent confidence interval, 0.57 to 1.13; P=0.42) during the three years of treatment. Prespecified analyses of the treatment effects at 6-month intervals showed that as compared with the placebo group, the donepezil group had a reduced likelihood of progression to Alzheimer's disease during the first 12 months of the study (P=0.04), a finding supported by the secondary outcome measures. Among carriers of one or more apolipoprotein E 4 alleles, the benefit of donepezil was evident throughout the three-year follow-up. There were no significant differences in the rate of progression to Alzheimer's disease between the vitamin E and placebo groups at any point, either among all patients or among apolipoprotein E 4 carriers.

Conclusions Vitamin E had no benefit in patients with mild cognitive impairment. Although donepezil therapy was associated with a lower rate of progression to Alzheimer's disease during the first 12 months of treatment, the rate of progression to Alzheimer's disease after three years was not lower among patients treated with donepezil than among those given placebo.

Source Information

From the Mayo Clinic College of Medicine, Rochester, Minn. (R.C.P.); University of California, San Diego, San Diego (R.G.T., D.G., S.J., L.J.T.); Elan Pharmaceuticals, San Diego (M.G.); Rush University Medical School, Chicago (D.B.); Baylor College of Medicine, Houston (R.D.); New York University, New York (S.F.); Oregon Health and Science University, Portland (J.K.); Emory University, Atlanta (A.L.); University of South Florida, Tampa (E.P.); Mt. Sinai School of Medicine, New York (M.S.); and Yale University, New Haven, Conn. (C.H.D.).

This article was published at www.nejm.org on April 13, 2005.

Address reprint requests to Dr. Petersen at the Alzheimer's Disease Research Center, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, or at peter8{at}mayo.edu.

Full Text of this Article

This article has been cited by other articles:

• Buchman, A. S., Boyle, P. A., Wilson, R. S., Fleischman, D. A., Leurgans, S., Bennett, D. A. (2009). Association Between Late-Life Social Activity and Motor Decline in Older Adults. Arch Intern Med 169: 1139-1146 [Abstract] [Full Text]  
• Lu, P. H., Edland, S. D., Teng, E., Tingus, K., Petersen, R. C., Cummings, J. L., On behalf of The Alzheimer's Disease Cooperative S, (2009). Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 72: 2115-2121 [Abstract] [Full Text]  
• Kang, J. H., Cook, N. R., Manson, J. E., Buring, J. E., Albert, C. M., Grodstein, F. (2009). Vitamin E, Vitamin C, Beta Carotene, and Cognitive Function Among Women With or at Risk of Cardiovascular Disease: The Women's Antioxidant and Cardiovascular Study. Circulation 119: 2772-2780 [Abstract] [Full Text]  
• Desikan, R. S., Cabral, H. J., Hess, C. P., Dillon, W. P., Glastonbury, C. M., Weiner, M. W., Schmansky, N. J., Greve, D. N., Salat, D. H., Buckner, R. L., Fischl, B., Alzheimer's Disease Neuroimaging Initiative, (2009). Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 0: awp123v1-awp123 [Abstract] [Full Text]  
• Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R., Watkins, W. E., Xu, Y., Murthy, A. K. (2009). Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial. Neurology 72: 1555-1561 [Abstract] [Full Text]  
• Knopman, D. S. (2009). Cracking the therapeutic nut in mild cognitive impairment: Better nuts and better nutcrackers. Neurology 72: 1542-1543 [Full Text]  
• Mitsushima, D., Takase, K., Funabashi, T., Kimura, F. (2009). Gonadal Steroids Maintain 24 h Acetylcholine Release in the Hippocampus: Organizational and Activational Effects in Behaving Rats. J. Neurosci. 29: 3808-3815 [Abstract] [Full Text]  
• Desikan, R.S., Cabral, H.J., Fischl, B., Guttmann, C.R.G., Blacker, D., Hyman, B.T., Albert, M.S., Killiany, R.J. (2009). Temporoparietal MR Imaging Measures of Atrophy in Subjects with Mild Cognitive Impairment That Predict Subsequent Diagnosis of Alzheimer Disease. Am. J. Neuroradiol. 30: 532-538 [Abstract] [Full Text]  
• Berry, D., Wathen, J. K., Newell, M. (2009). Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clin Trials 6: 28-41 [Abstract]  
• Petrella, J.R., Prince, S.E., Krishnan, S., Husn, H., Kelley, L., Doraiswamy, P.M. (2009). Effects of Donepezil on Cortical Activation in Mild Cognitive Impairment: A Pilot Double-Blind Placebo-Controlled Trial Using Functional MR Imaging. Am. J. Neuroradiol. 30: 411-416 [Abstract] [Full Text]  
• Scarmeas, N., Stern, Y., Mayeux, R., Manly, J. J., Schupf, N., Luchsinger, J. A. (2009). Mediterranean Diet and Mild Cognitive Impairment. Arch Neurol 66: 216-225 [Abstract] [Full Text]  
• Meeks, T. W., Lanouette, N., Vahia, I., Dawes, S., Jeste, D. V., Lebowitz, B. (2009). Psychiatric Assessment and Diagnosis in Older Adults. Focus 7: 3-16 [Abstract] [Full Text]  
• SALLOWAY, S., CORREIA, S. (2009). Alzheimer disease: Time to improve its diagnosis and treatment. Cleveland Clinic Journal of Medicine 76: 49-58 [Abstract] [Full Text]  
• Chertkow, H., Massoud, F., Nasreddine, Z., Belleville, S., Joanette, Y., Bocti, C., Drolet, V., Kirk, J., Freedman, M., Bergman, H. (2009). Diagnosis and Treatment of Dementia: 3. Mild Cognitive Impairment and Cognitive Impairment Without Dementia. Focus 7: 64-78 [Abstract] [Full Text]  
• Wright, J. W, Harding, J. W (2008). The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease. Journal of Renin-Angiotensin-Aldosterone System 9: 226-237 [Abstract]  
• Rozzini, L., Vicini Chilovi, B., Bertoletti, E., Conti, M., Delrio, I., Trabucchi, M., Padovani, A. (2008). The Importance of Alzheimer Disease Assessment Scale-cognitive Part in Predicting Progress for Amnestic Mild Cognitive Impairment to Alzheimer Disease. J Geriatr Psychiatry Neurol 21: 261-267 [Abstract]  
• Mitchell, A J, Shiri-Feshki, M (2008). Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J. Neurol. Neurosurg. Psychiatry 79: 1386-1391 [Abstract] [Full Text]  
• Dassel, K. B., Schmitt, F. A. (2008). The Impact of Caregiver Executive Skills on Reports of Patient Functioning. Gerontologist 48: 781-792 [Abstract] [Full Text]  
• Hogan, D. B. MD, Bailey, P. MD, Black, S. MD, Carswell, A. MSc PhD, Chertkow, H. MD, Clarke, B. MD, Cohen, C. BA MD, Fisk, J. D. PhD, Forbes, D. RN PhD, Man-Son-Hing, M. MSc MD, Lanctot, K. PhD, Morgan, D. RN PhD, Thorpe, L. MD PhD (2008). Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ 179: 1019-1026 [Abstract] [Full Text]  
• Okonkwo, O. C., Griffith, H. R., Copeland, J. N., Belue, K., Lanza, S., Zamrini, E. Y., Harrell, L. E., Brockington, J. C., Clark, D., Raman, R., Marson, D. C. (2008). Medical decision-making capacity in mild cognitive impairment: A 3-year longitudinal study. Neurology 71: 1474-1480 [Abstract] [Full Text]  
• Molnar, F. J. MSc MDCM, Hutton, B. MSc, Fergusson, D. MHA PhD (2008). Does analysis using "last observation carried forward" introduce bias in dementia research?. CMAJ 179: 751-753 [Full Text]  
• Geda, Y. E., Roberts, R. O., Knopman, D. S., Petersen, R. C., Christianson, T. J. H., Pankratz, V. S., Smith, G. E., Boeve, B. F., Ivnik, R. J., Tangalos, E. G., Rocca, W. A. (2008). Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Normal Cognitive Aging: Population-Based Study. Arch Gen Psychiatry 65: 1193-1198 [Abstract] [Full Text]  
• Ellison, J. M. (2008). A 60-Year-Old Woman With Mild Memory Impairment: Review of Mild Cognitive Impairment. JAMA 300: 1566-1574 [Abstract] [Full Text]  
• Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., Hamel, E. (2008). Complete Rescue of Cerebrovascular Function in Aged Alzheimer's Disease Transgenic Mice by Antioxidants and Pioglitazone, a Peroxisome Proliferator-Activated Receptor {gamma} Agonist. J. Neurosci. 28: 9287-9296 [Abstract] [Full Text]  
• Lautenschlager, N. T., Cox, K. L., Flicker, L., Foster, J. K., van Bockxmeer, F. M., Xiao, J., Greenop, K. R., Almeida, O. P. (2008). Effect of Physical Activity on Cognitive Function in Older Adults at Risk for Alzheimer Disease: A Randomized Trial. JAMA 300: 1027-1037 [Abstract] [Full Text]  
• Larson, E. B. (2008). Physical Activity for Older Adults at Risk for Alzheimer Disease. JAMA 300: 1077-1079 [Full Text]  
• Yesavage, J. A., Friedman, L., Ashford, J. W., Kraemer, H. C., Mumenthaler, M. S., Noda, A., Hoblyn, J. (2008). Acetylcholinesterase Inhibitor in Combination With Cognitive Training in Older Adults. Journals of Gerontology Series B: Psychological Sciences and Social Science 63: P288-P294 [Abstract] [Full Text]  
• Caselli, R. J., Chen, K., Lee, W., Alexander, G. E., Reiman, E. M. (2008). Correlating Cerebral Hypometabolism With Future Memory Decline in Subsequent Converters to Amnestic Pre-Mild Cognitive Impairment. Arch Neurol 65: 1231-1236 [Abstract] [Full Text]  
• Nestor, S. M., Rupsingh, R., Borrie, M., Smith, M., Accomazzi, V., Wells, J. L., Fogarty, J., Bartha, R., the Alzheimer's Disease Neuroimaging Initiative, (2008). Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain 131: 2443-2454 [Abstract] [Full Text]  
• Myers, C. E., Kluger, A., Golomb, J., Gluck, M. A., Ferris, S. (2008). Learning and Generalization Tasks Predict Short-Term Cognitive Outcome in Nondemented Elderly. J Geriatr Psychiatry Neurol 21: 93-103 [Abstract]  
• Lee, J.-Y., Dong Woo Lee, , Cho, S.-J., Na, D. L., Hong Jin Jeon, , Kim, S.-K., You Ra Lee, , Youn, J.-H., Kwon, M., Lee, J.-H., Maeng Je Cho, (2008). Brief Screening for Mild Cognitive Impairment in Elderly Outpatient Clinic: Validation of the Korean Version of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol 21: 104-110 [Abstract]  
• Aisen, P. S. (2008). Treatment for MCI: Is the evidence sufficient?. Neurology 70: 2020-2021 [Full Text]  
• Winblad, B., Gauthier, S., Scinto, L., Feldman, H., Wilcock, G. K., Truyen, L., Mayorga, A. J., Wang, D., Brashear, H. R., Nye, J. S., The GAL-INT-11/18 Study Group, (2008). Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70: 2024-2035 [Abstract] [Full Text]  
• Chertkow, H. MD, Massoud, F. MD, Nasreddine, Z. MD, Belleville, S. PhD, Joanette, Y. PhD, Bocti, C. MD, Drolet, V. BSc, Kirk, J. MD, Freedman, M. MD, Bergman, H. MD (2008). Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ 178: 1273-1285 [Abstract] [Full Text]  
• Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., Steffens, D. C., McArdle, J. J., Willis, R. J., Wallace, R. B. (2008). Prevalence of Cognitive Impairment without Dementia in the United States. ANN INTERN MED 148: 427-434 [Abstract] [Full Text]  
• Brust, J. C. M. (2008). A 74-Year-Old Man With Memory Loss and Neuropathy Who Enjoys Alcoholic Beverages. JAMA 299: 1046-1054 [Abstract] [Full Text]  
• Qaseem, A., Snow, V., Cross, J. T. Jr., Forciea, M. A., Hopkins, R. Jr., Shekelle, P., Adelman, A., Mehr, D., Schellhase, K., Campos-Outcalt, D., Santaguida, P., Owens, D. K., the Joint American College of Physicians/American, (2008). Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. ANN INTERN MED 148: 370-378 [Abstract] [Full Text]  
• Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., Oremus, M. (2008). Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline. ANN INTERN MED 148: 379-397 [Abstract] [Full Text]  
• Fleisher, A. S., Sun, S., Taylor, C., Ward, C. P., Gamst, A. C., Petersen, R. C., Jack, C. R. Jr, Aisen, P. S., Thal, L. J., For the Alzheimer's Disease Cooperative Study, (2008). Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 70: 191-199 [Abstract] [Full Text]  
• Dickerson, B. C., Sperling, R. A., Hyman, B. T., Albert, M. S., Blacker, D. (2007). Clinical Prediction of Alzheimer Disease Dementia Across the Spectrum of Mild Cognitive Impairment. Arch Gen Psychiatry 64: 1443-1450 [Abstract] [Full Text]  
• Barberger-Gateau, P., Raffaitin, C., Letenneur, L., Berr, C., Tzourio, C., Dartigues, J. F., Alperovitch, A. (2007). Dietary patterns and risk of dementia: The Three-City cohort study. Neurology 69: 1921-1930 [Abstract] [Full Text]  
• Yaffe, K. (2007). Antioxidants and Prevention of Cognitive Decline: Does Duration of Use Matter?. Arch Intern Med 167: 2167-2168 [Full Text]  
• Grodstein, F., Kang, J. H., Glynn, R. J., Cook, N. R., Gaziano, J. M. (2007). A Randomized Trial of Beta Carotene Supplementation and Cognitive Function in Men: The Physicians' Health Study II. Arch Intern Med 167: 2184-2190 [Abstract] [Full Text]  
• Boeve, B. F., Silber, M. H., Saper, C. B., Ferman, T. J., Dickson, D. W., Parisi, J. E., Benarroch, E. E., Ahlskog, J. E., Smith, G. E., Caselli, R. C., Tippman-Peikert, M., Olson, E. J., Lin, S.-C., Young, T., Wszolek, Z., Schenck, C. H., Mahowald, M. W., Castillo, P. R., Del Tredici, K., Braak, H. (2007). Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 130: 2770-2788 [Abstract] [Full Text]  
• Cummings, J. L., Doody, R., Clark, C. (2007). Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology 69: 1622-1634 [Abstract] [Full Text]  
• Okonkwo, O., Griffith, H. R., Belue, K., Lanza, S., Zamrini, E. Y., Harrell, L. E., Brockington, J. C., Clark, D., Raman, R., Marson, D. C. (2007). Medical decision-making capacity in patients with mild cognitive impairment. Neurology 69: 1528-1535 [Abstract] [Full Text]  
• Petrella, J. R., Wang, L., Krishnan, S., Slavin, M. J., Prince, S. E., Tran, T.-T. T., Doraiswamy, P. M. (2007). Cortical Deactivation in Mild Cognitive Impairment: High-Field-Strength Functional MR Imaging. Radiology 245: 224-235 [Abstract] [Full Text]  
• Lu, Y.-F. Y., Austrom, M. G., Perkins, S. M., Bakas, T., Farlow, M. R., Feng He, , Shelia Jin, , Gamst, A. (2007). Depressed Mood in Informal Caregivers of Individuals With Mild Cognitive Impairment. AM J ALZHEIMERS DIS OTHER DEMEN 22: 273-285 [Abstract]  
• Ikonomovic, M. D., Abrahamson, E. E., Isanski, B. A., Wuu, J., Mufson, E. J., DeKosky, S. T. (2007). Superior Frontal Cortex Cholinergic Axon Density in Mild Cognitive Impairment and Early Alzheimer Disease. Arch Neurol 64: 1312-1317 [Abstract] [Full Text]  
• Harrison, J., Minassian, S. L., Jenkins, L., Black, R. S., Koller, M., Grundman, M. (2007). A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials. Arch Neurol 64: 1323-1329 [Abstract] [Full Text]  
• Swanson, K. A., Carnahan, R. M. (2007). Dementia and Comorbidities: An Overview of Diagnosis and Management. Journal of Pharmacy Practice 20: 296-317 [Abstract]  
• Whitwell, J. L., Petersen, R. C., Negash, S., Weigand, S. D., Kantarci, K., Ivnik, R. J., Knopman, D. S., Boeve, B. F., Smith, G. E., Jack, C. R. Jr (2007). Patterns of Atrophy Differ Among Specific Subtypes of Mild Cognitive Impairment. Arch Neurol 64: 1130-1138 [Abstract] [Full Text]  
• Markesbery, W. R., Lovell, M. A. (2007). Damage to Lipids, Proteins, DNA, and RNA in Mild Cognitive Impairment. Arch Neurol 64: 954-956 [Abstract] [Full Text]  
• Perneczky, R., Hartmann, J., Grimmer, T., Drzezga, A., Kurz, A. (2007). Cerebral Metabolic Correlates of the Clinical Dementia Rating Scale in Mild Cognitive Impairment. J Geriatr Psychiatry Neurol 20: 84-88 [Abstract]  
• Blacker, D., Lee, H., Muzikansky, A., Martin, E. C., Tanzi, R., McArdle, J. J., Moss, M., Albert, M. (2007). Neuropsychological Measures in Normal Individuals That Predict Subsequent Cognitive Decline. Arch Neurol 64: 862-871 [Abstract] [Full Text]  
• Yesavage, J., Hoblyn, J., Friedman, L., Mumenthaler, M., Schneider, B., O'Hara, R. (2007). Should One Use Medications in Combination With Cognitive Training? If So, Which Ones?. Journals of Gerontology Series B: Psychological Sciences and Social Science 62: 11-18 [Abstract] [Full Text]  
• Fleisher, A. S., Sowell, B. B., Taylor, C., Gamst, A. C., Petersen, R. C., Thal, L. J., for the Alzheimer's Disease Cooperative Study, (2007). Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 68: 1588-1595 [Abstract] [Full Text]  
• Johnson, K A, Moran, E K, Becker, J A, Blacker, D, Fischman, A J, Albert, M S (2007). Single photon emission computed tomography perfusion differences in mild cognitive impairment. J. Neurol. Neurosurg. Psychiatry 78: 240-247 [Abstract] [Full Text]  
• Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., Gluud, C. (2007). Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis. JAMA 297: 842-857 [Abstract] [Full Text]  
• Fischer, P., Jungwirth, S., Zehetmayer, S., Weissgram, S., Hoenigschnabl, S., Gelpi, E., Krampla, W., Tragl, K. H. (2007). Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 68: 288-291 [Abstract] [Full Text]  
• von Haehling, S., Doehner, W., Anker, S. D (2007). Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 73: 298-309 [Abstract] [Full Text]  
• DeCarli, C., Frisoni, G. B., Clark, C. M., Harvey, D., Grundman, M., Petersen, R. C., Thal, L. J., Jin, S., Jack, C. R. Jr, Scheltens, P., for the Alzheimer's Disease Cooperative Study Grou, (2007). Qualitative Estimates of Medial Temporal Atrophy as a Predictor of Progression From Mild Cognitive Impairment to Dementia. Arch Neurol 64: 108-115 [Abstract] [Full Text]  
• Shumaker, S. A., Legault, C., Coker, L. H. (2006). Behavior-Based Interventions to Enhance Cognitive Functioning and Independence in Older Adults. JAMA 296: 2852-2854 [Full Text]  
• Espeland, M. A., Henderson, V. W. (2006). Preventing Cognitive Decline in Usual Aging. Arch Intern Med 166: 2433-2434 [Full Text]  
• Kang, J. H., Cook, N., Manson, J., Buring, J. E., Grodstein, F. (2006). A Randomized Trial of Vitamin E Supplementation and Cognitive Function in Women. Arch Intern Med 166: 2462-2468 [Abstract] [Full Text]  
• Hunderfund, A. L., Roberts, R. O., Slusser, T. C., Leibson, C. L., Geda, Y. E., Ivnik, R. J., Tangalos, E. G., Petersen, R. C. (2006). Mortality in amnestic mild cognitive impairment: A prospective community study. Neurology 67: 1764-1768 [Abstract] [Full Text]  
• Petersen, R. C. (2006). Conversion.. Neurology 67: S12-S13 [Abstract] [Full Text]  
• Burns, A., O'Brien, J. (2006). Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 20: 732-755 [Abstract]  
• Rosenberg, P. B., Johnston, D., Lyketsos, C. G. (2006). A Clinical Approach to Mild Cognitive Impairment. Am. J. Psychiatry 163: 1884-1890 [Full Text]  
• Gamaldo, A., Moghekar, A., Kilada, S., Resnick, S. M., Zonderman, A. B., O'Brien, R. (2006). Effect of a clinical stroke on the risk of dementia in a prospective cohort. Neurology 67: 1363-1369 [Abstract] [Full Text]  
• Rose, S E, McMahon, K L, Janke, A L, O'Dowd, B, de Zubicaray, G, Strudwick, M W, Chalk, J B (2006). Diffusion indices on magnetic resonance imaging and neuropsychological performance in amnestic mild cognitive impairment. J. Neurol. Neurosurg. Psychiatry 77: 1122-1128 [Abstract] [Full Text]  
• Petersen, R. C., O'Brien, J. (2006). Mild Cognitive Impairment Should Be Considered for DSM-V. J Geriatr Psychiatry Neurol 19: 147-154 [Abstract]  
• Sano, M. (2006). Neuropsychological Testing in the Diagnosis of Dementia. J Geriatr Psychiatry Neurol 19: 155-159 [Abstract]  
• Blacker, D., Lovestone, S. (2006). Genetics and Dementia Nosology. J Geriatr Psychiatry Neurol 19: 186-191 [Abstract]  
• Storandt, M., Grant, E. A., Miller, J. P., Morris, J. C. (2006). Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 67: 467-473 [Abstract] [Full Text]  
• Knight, C. L., Fihn, S. D. (2006). Update in General Internal Medicine. ANN INTERN MED 145: 52-61 [Full Text]  
• Lopez-Pousa, S., Olmo, J. G., Franch, J. V., Estrada, A. T., Cors, O. S., Nierga, I. P., Gelada-Batlle, E. (2006). Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.. Age Ageing 35: 365-371 [Abstract] [Full Text]  
• Callahan, C. M., Boustani, M. A., Unverzagt, F. W., Austrom, M. G., Damush, T. M., Perkins, A. J., Fultz, B. A., Hui, S. L., Counsell, S. R., Hendrie, H. C. (2006). Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial.. JAMA 295: 2148-2157 [Abstract] [Full Text]  
• Petersen, R. C., Parisi, J. E., Dickson, D. W., Johnson, K. A., Knopman, D. S., Boeve, B. F., Jicha, G. A., Ivnik, R. J., Smith, G. E., Tangalos, E. G., Braak, H., Kokmen, E. (2006). Neuropathologic Features of Amnestic Mild Cognitive Impairment. Arch Neurol 63: 665-672 [Abstract] [Full Text]  
• Jicha, G. A., Parisi, J. E., Dickson, D. W., Johnson, K., Cha, R., Ivnik, R. J., Tangalos, E. G., Boeve, B. F., Knopman, D. S., Braak, H., Petersen, R. C. (2006). Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.. Arch Neurol 63: 674-681 [Abstract] [Full Text]  
• Jelic, V, Kivipelto, M, Winblad, B (2006). Clinical trials in mild cognitive impairment: lessons for the future. J. Neurol. Neurosurg. Psychiatry 77: 429-438 [Abstract] [Full Text]  
• Boeve, B. F., Saper, C. B. (2006). REM sleep behavior disorder: A possible early marker for synucleinopathies. Neurology 66: 796-797 [Full Text]  
• Verghese, J., LeValley, A., Derby, C., Kuslansky, G., Katz, M., Hall, C., Buschke, H., Lipton, R. B. (2006). Leisure activities and the risk of amnestic mild cognitive impairment in the elderly. Neurology 66: 821-827 [Abstract] [Full Text]  
• Claassen, J. A. H. R., Jansen, R. W. M. M. (2006). Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis.. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 61: 267-271 [Abstract] [Full Text]  
• Blacker, D. (2006). Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer's disease in the long term. Evid. Based Ment. Health 9: 20-20 [Full Text]  
• Morris, J. C. (2006). Mild Cognitive Impairment Is Early-Stage Alzheimer Disease: Time to Revise Diagnostic Criteria. Arch Neurol 63: 15-16 [Full Text]  
• Hu, Y., Malone, J. P., Fagan, A. M., Townsend, R. R., Holtzman, D. M. (2005). Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid. Mol. Cell. Proteomics 4: 2000-2009 [Abstract] [Full Text]  
• Fillenbaum, G. G, Kuchibhatla, M. N, Hanlon, J. T, Artz, M. B, Pieper, C. F, Schmader, K. E, Dysken, M. W, Gray, S. L (2005). Dementia and Alzheimer's Disease in Community-Dwelling Elders Taking Vitamin C and/or Vitamin E. The Annals of Pharmacotherapy 39: 2009-2014 [Abstract] [Full Text]  
• Boothby, L. A, Doering, P. L (2005). Vitamin C and Vitamin E for Alzheimer's Disease. The Annals of Pharmacotherapy 39: 2073-2079 [Abstract] [Full Text]  
• Pham, D. Q, Plakogiannis, R. (2005). Vitamin E Supplementation in Alzheimer's Disease, Parkinson's Disease, Tardive Dyskinesia, and Cataract: Part 2. The Annals of Pharmacotherapy 39: 2065-2071 [Abstract] [Full Text]  
• Farlow, M. R. (2005). The search for disease modification in moderate to severe Alzheimer disease: A critical review of current evidence. Neurology 65: S25-S30 [Full Text]  
• (2005). Vitamin E, donepezil don't slow progression of mild cognitive impairment. BMJ 331: - [Full Text]